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Abstract
Background: Mercuric chloride (HgCl2) induces an autoimmune nephritis in the Brown Norway (BN) rats characterized
by anti-glomerular basement membrane antibodies (anti-GBM Ab) deposition, proteinuria and a severe interstitial nephritis,
all evident at day 13 of the disease. We assessed the effects of all-trans retinoic acid (at-RA) in this experimental model.
At-RA is a vitamin A metabolite which has shown beneficial effects on several nephropathies, even though no clear targets
for at-RA were provided.
Methods: We separated animals in four different experimental groups (HgCl2, HgCl2+at-RA, at-RA and vehicle). From
each animal we collected, at days 0 and 13, numerous biological samples: urine, to measure proteinuria by colorimetry;
blood to determine VLA-4 expression by flow citometry; renal tissue to study the expression of VCAM-1 by Western blot,
the presence of cellular infiltrates by immunohistochemistry, the IgG deposition by immunofluorescence, and the cytokines
expression by RT-PCR. Additionally, adhesion assays to VCAM-1 were performed using K562 α4 transfectant cells.
ANOVA tests were used for statistical significance estimation.
Results: We found that at-RA significantly decreased the serum levels of anti-GBM and consequently its deposition along
the glomerular membrane. At-RA markedly reduced proteinuria as well as the number of cellular infiltrates in the renal
interstitium, the levels of TNF-α and IL-1β cytokines and VCAM-1 expression in renal tissue. Moreover, we reported here
for the first time in an in vivo model that at-RA reduced, to basal levels, the expression of VLA-4 (α4β1) integrin induced
by mercury on peripheral blood leukocytes (PBLs). In addition, using K562 α4 stable transfectant cells, we found that at-
RA inhibited VLA-4 dependent cell adhesion to VCAM-1.
Conclusion: Here we demonstrate a therapeutic effect of at-RA on an autoimmune experimental nephritis model in rats.
We report a significant reduction of the VLA-4 integrin expression on PBLs as well as the inhibition of the VLA4/VCAM1-
dependent leukocyte adhesion by at-RA treatment. Thereby we point out the VLA-4 integrin as a target for at-RA in vivo.
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Background
Brown Norway (BN) rats receiving sublethal doses of
HgCl2  develop a self-limiting autoimmune syndrome
characterized by the presence of an autoreactive Th2 CD4+
cell subset [1-3]. This autoimmune response is accompa-
nied by synthesis and linear anti-GBM IgG Ab deposition
as well as severe proteinuria. The histological renal lesions
consist of a mild and transient glomerular influx of circu-
lating leukocytes and a severe and persistent cell infiltrate
in the renal interstitium that reach the maximum at day
13 of the disease [3]
The vitamin A metabolite, at-RA, which regulates a broad
range of biological processes, has been reported to be a
beneficial treatment in the rat model of anti-Thy1.1
mesangioproliferative glomerulonephritis, reducing
mesangial expansion and proteinuria [4] as well as in the
glomerulonephritis induced by anti-GBM antibodies,
ameliorating necrosis and urinary protein excretion [5].
These previous evidences of at-RA effects on experimental
renal models of diseases suggest that this compound
could have beneficial effects on the development of an
inflammatory and autoimmune response in the kidney.
Up to the moment, the mechanisms and the targets
through which at-RA treatment improves renal diseases
outcome remains quite unexplored.
For the development of an inflammatory response, as the
one evidenced in this experimental model, it is well
known that the interaction of the circulating leukocytes
with the endothelium and the subsequent extravasation
into tissues is necessary [6], as well as T-B cells interaction,
in the development of an autoimmune response, [7] also
present in this experimental model. In this regard, previ-
ous results from our laboratory described that VLA-4
integrin is critical for leukocyte migration from blood to
renal tissue in HgCl2-induced nephritis [8,9]. In addition,
VLA-4 not only mediates the adhesion and trans-endothe-
lial migration of leukocytes, but also provides co-stimula-
tory signals that contribute to the activation of T
lymphocytes and participates in the immunological syn-
apse between antigen presenting cells and T cells [10],
thus underscoring the important role of VLA-4 in this
experimental model.
On the other hand, it has been described that at-RA mod-
ulates the expression and function of β2 integrins in pri-
mary human monocytes [11]. In addition, it has been
reported that at-RA abolished in vitro α4 integrin depend-
ent rolling in the acute promyelocytic leukaemia cell line
NB-4 [12]. However, there are not previous evidences
regarding to the modulation of VLA-4 integrin expression
and function by at-RA in vivo.
Conversely, cytokines such as IL-1β and TNF-α stimulate
the expression of adhesion molecules required for leuko-
cyte adhesion and migration in endothelial cells [13].
Besides, it has been reported that at-RA affects VCAM-1
expression in a dermal microvascular endothelium cell
line by modulating the expression of TNF-α [14].
We have therefore studied, using an experimental in vivo
model of autoimmune nephritis in rats, the effect of at-RA
in the outcome of this renal disease. We reported herein
that at-RA significantly reduces VLA-4 expression and
function as well as VCAM-1 expression, both mediating,
among others, the beneficial effect of at-RA in this neph-
ropathy. Moreover, the present work identifies for the first
time the VLA-4 integrin as a target for at-RA in vivo.
Methods
Animals
Male BN rats, weighting 150 to 180 g, were obtained from
IFFA-CREDO (Paris, France) and from our own breeding
colony, fed with standard laboratory chow ad libitum and
given free access to water. All experimental procedures
were performed according to the institutional guidelines
that are in compliance with the National Institute of
Health Guide for the Care Use of Laboratory animals.
Cell culture
The human cell line K562 was grown in RPMI 1640 sup-
plemented with 10% fetal bovine serum, 2 mM
glutamine, 100 U/ml penicillin and 100 µg/ml streptomy-
cin (Invitrogen), considered as complete medium, in a
humidified atmosphere with 5% CO2, at 37°C. K562-α4
cells (K562 transfected with α4 cDNA) were maintained
in complete medium also containing 1.5 mg/ml G418
(GIBCO) [15]. Both cell lines were treated with 50, 100
and 500 nM at-RA during 24, 48 and 72 h.
Experimental in vivo design
Animals were divided into four different groups. Group I
(n = 10) received five subcutaneous injections of HgCl2 (1
mg/Kg body weight) over a period of two weeks for induc-
ing the disease and was considered as positive control
group (the HgCl2 injections start at day 0 of the experi-
ment). The dosage and days were chosen based on previ-
ous optimizing experiments [9]. The following two
groups of rats (Groups II and III) were treated from day 0
of the experimental protocol with chow pellet supple-
mented with at-RA (15 mg/Kg body weight). At-RA sup-
plemented chow pellets were prepared daily using a 1.68
mg/ml ethanol at-RA stock solution, as previously
described [16], and mixed in a dark cold room with stand-
ard chow. After the ethanol evaporated, the food was
given to the rats. Group II (n = 15) was formed by rats
injected with HgCl2 and treated with at-RA (15 mg/Kg)
and group III (n = 10) by rats only treated with at-RA.BMC Nephrology 2007, 8:3 http://www.biomedcentral.com/1471-2369/8/3
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Finally, in group IV (n = 10) rats were injected with H2O
adjusted at the same pH (3.8) as the HgCl2solution, fol-
lowing the same protocol of HgCl2 administration and
this group was considered as control group.
Proteinuria
Rats were housed in metabolic cages with free access to
food and water to collect 24 h urine. Urine samples were
taken at day 0 and day 13th. Protein concentration in
urine was determined by Bio-Rad assay (Bio-Rad, Rich-
mond, CA) according to the manufacturer's protocol.
Samples were assayed in triplicate, and the optical density
from each one was measured at 595 nm in a Titertek Mul-
tiskan Plus (Flow, Irvine, Scotland).
Anti- GBM abs assay
Rat GBM was isolated as described [17]. Briefly, glomeruli
were obtained from healthy BN rats by differential sieving
and centrifugation of minced kidney cortices. The glomer-
ular suspension was sonicated, washed and lyophilized.
The GBM was digested by collagenase I (Sigma Chemical
Co., St. Louis, MO) at 0.7% wt/wt at 37°C for 1 h. Anti-
GBM Abs in serum were measured by ELISA, as previously
described [17] using rat GBM extracted as adhesion sub-
strate for the anti-GBM Abs. All the samples were assayed
in triplicate. Samples of a serum pool from untreated BN
rats and from mercury-treated BN (which were blended at
day 13 of the disease) served as negative and positive con-
trols, respectively. Results were expressed as percentage of
binding relative to samples from positive control serum.
Absorbance was measured at 492 nm using the Titertek
Multiskan Plus.
Kidney tissue processing
Kidneys were removed at day 13 of the disease and studies
were performed on paraffin-embedded tissue and cryosec-
tions. For light microscopy, a piece of tissue was fixed in
phosphate-buffered 10% formalin, and 3 µm paraffin-
embedded kidney sections were stained with periodic
acid-Shiff (PAS). An indirect peroxidase stained method
was used to characterize CD68+cells (anti-rat monocyte/
macrophages) and CD3+cells (anti-rat T lymphocytes), in
the renal interstitium [8,18]. These antibodies were
obtained from Serotec (Oxford, U.K). Quantification of
interstitial infiltrating cells bearing positive CD68 and
CD3 cell surface markers was performed by counting, in
two kidney tissue sections per each rat, the total number
of positive labelled cells examined in ten randomly cho-
sen areas of interstitial infiltrates, as previously described
[19]. Kidney tissue cryosections (5 µm) fixed in ether/eth-
anol, were used for VLA-4+ cells detection with the mouse
anti-human HP2/1 mAb directed towards the α4 integrin
that cross-reacts with rat α4 integrin [8], following the
same indirect peroxidase method as described above.
Direct immunofluorescence studies were also performed
on ether/ethanol fixed serial kidney tissue cryostat sec-
tions using FITC-conjugated rabbit anti-rat IgG Ab from
Serotec (Oxford, U.K), as described [20]. Finally, the fluo-
rescence intensity of IgG deposits was quantified using
ScionImage software in five different fields from three
independent sections in all experimental groups.
Protein extraction and western blot analysis
Pieces of renal tissue were snap-frozen in liquid nitrogen
and lysed in 100 mM phosphate (pH 7.6) buffer contain-
ing: 150 nM NaCl, 10 mM EDTA, 0.5% Triton X-100 and
phosphatase (1 mM FNa, 2 mM ONa) and protease inhib-
itors (10 mg/ml leupeptin, 10 mg/ml aprotinin, 25 mM
AEBSF). Homogenized tissue was incubated on ice for
30–60 min and lysates were centrifuged at 13000 × g for
30 min at 4°C. Supernatants were collected and protein
concentration was quantified by Bradford colorimetric
assay. Whole kidney lysates were separated by SDS-PAGE
and transferred onto PVDF membranes (Millipore, Bed-
ford, MA). Membranes were incubated in blocking solu-
tion for 1 hour. Anti-VCAM-1 Ab and anti-actin (Santa
Cruz, CA) were diluted in Tris- Buffered saline, 0.05%
Tween containing 1% BSA (Sigma) and membranes were
incubated overnight at 4°C. The secondary antibodies
rabbit anti-goat HRP-conjugated (Jakson ImmunoRe-
search, PA), diluted in the same buffer mentioned above,
were incubated at room temperature for 1 h. Specific
bands were visualized by ECL Western Blotting detection
system (Amersham Pharmacia Biotech).
Reverse transcriptase polymerase chain reaction (RT-PCR)
For quantitative reverse transcriptase polymerase chain
reaction (RT-PCR), snap-frozen kidney tissues from all
experimental groups of rats were homogenized with a Pol-
ytron® (Kinematica, Littau, Switzerland) and total RNA
was obtained using the Ultraspec RNA isolation system
(Biotecx, Houston, Texas). 2 µg of DNaseI-treated RNA
was reverse transcribed with MuLV reverse transcriptase
(Roche). mRNA expression was quantified by real-time
PCR following the manufacturer's instructions (Lightcy-
cler rapid thermal cycler, Roche) using the primers specific
for sequences from different exons that generated prod-
ucts (5'→3'): ATG CCA TCC TGC GTC TGG ACC TGG C
(β-actin, sense), AGC ATT TGC GGT GCA CGA TGG C (β-
actin-antisense), CAC CTC TCA AGC AGA GCA CAG (IL-
1β-sense), GGG TTC CAT GGT GAA GTC AAC (IL-1β-anti-
sense), CCA GGA GAA AGT CAG CCT CCT (TNFα-sense),
TCA TAC CAG GGC TTG AGC TCA (TNFα-antisense).
Results for the expression of each cytokine were normal-
ized to expression and both cytokine and β-actin were
measured in each sample.
Flow cytometry assay
Whole-blood samples of heparinized blood (100 µl aliq-
uots) were incubated with saturating concentrations ofBMC Nephrology 2007, 8:3 http://www.biomedcentral.com/1471-2369/8/3
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anti-α4 HP2/1 at 4°C for 45 min. After washing with PBS,
the cells were incubated with goat anti-mouse FITC-con-
jugated (Jakson ImmunoResearch, PA) at 4°C for 30 min.
The erythrocytes were lysed with Quicklysis, following
manufacturer's instructions. Cells incubated only with the
secondary Ab served as negative control for non-specific
antibody binding. The samples were analyzed using FAC-
Scan cytometer (Becton Dickinson, Oxford, UK).
Cell adhesion assay
For cell adhesion, K562-α4 transfectants were labelled
with BCECF-AM (Molecular probes, Leiden, The Nether-
lands) for 30 min at 37°C, and some samples were also
pre-incubated with anti-α4 HP2/4. Then, 5 × 104/100 µl
cells were added in adhesion medium (RPMI containing
0.4% BSA) to 96-well dishes (High-binding; Costar, Cam-
bridge, MA) coated with sVCAM-1 1 µg/ml (R&D Sys-
tems). After incubation for 20 min at 37°C, unbound cells
were removed by three washes with RPMI medium and
adhered cells were quantified using a fluorescence ana-
lyzer (CytoFluor 2003; Millipore, Bedford, MA).
Statistical analyses
Proteinuria and ELISA results were given as mean ± SD.
The statistical analysis was performed by ANOVA analysis
and a P < 0.001 was considered significant.
Results
Effect of at-RA on proteinuria
To ascertain the effect of at-RA on characteristic parame-
ters for the HgCl2-induced nephritis, we first evaluated the
effect of at-RA on the protein excretion levels (Fig. 1). Pro-
teinuria from HgCl2-injected rats (group I) reaches signif-
icant values at day 13. When HgCl2-injected rats were
treated with at-RA, the urinary levels of protein excretion
showed an 80% reduction at day 13 of the disease. Rats
only treated with at-RA showed no modifications in uri-
nary protein levels as occurred in control rats.
Effect of at-RA on anti-GBM abs production and 
glomerular deposition
Next, the synthesis of anti-GBM auto-Ab was evaluated. As
shown in Fig. 2A, at day 13 of the disease HgCl2-injected
rats showed an increase of anti-GBM Ab circulating levels
in the serum (group I) estimated by ELISA. In addition, a
positive linear pattern of rat IgG deposits along the GBM
was detected by direct immunofluorescence in this exper-
imental group (Fig. 2B,a). Otherwise, rats that in addition
to mercury administration were treated also with at-RA
(group II) showed a significant decrease at day 13 in both
circulating serum levels (Fig. 2A) and glomerular deposi-
tion of IgG anti-GBM Ab (Fig. 2B,b). The IgG deposition
along the GBM was quantified measuring fluorescent
intensity emitted by the deposited Abs. This quantifica-
tion confirmed the significant reduction of anti-GBM Abs
deposition in kidney sections from HgCl2-injected rats
At-RA treatment reduces proteinuria Figure 1
At-RA treatment reduces proteinuria. Protein excretion in urine from all the experimental groups, measured by colori-
metric assay (Bradford Method). Results are expressed as mg of protein/24 h. Data are presented as mean ± SD; *P < 0.001 vs. 
vehicle group and °P < 0.001 vs. HgCl2 group;BMC Nephrology 2007, 8:3 http://www.biomedcentral.com/1471-2369/8/3
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also treated with at-RA in comparison to sections from
HgCl2-injected rats (Fig. 2B).
Effect of at-RA on renal interstitial cell infiltrates
Light microscopy examination of tissue sections stained
with PAS indicated that rats with HgCl2-induced nephritis
(group I), at day 13 of the disease, exhibited a pronounced
interstitial cell infiltration, preferentially located in the
perivascular region of the renal interstitium (Fig. 3A,a), in
comparison with those rats also treated with at-RA (group
II) (Fig. 3A,b). At day 13, quantification of interstitial cell
infiltrates showed a significant reduction in the number of
positive stained cells for lymphohaematopoietic markers
in those rats that in addition to HgCl2 were treated with at-
RA (CD3+ cells: 6 ± 0.78 cells/HPF and CD68+ cells: 5.75
± 0.75 cells/HPF) as compared with those rats injected
only with HgCl2 (CD3+ cells: 32 ± 2.08 cells/HPF and
CD68+: cells 25.50 ± 1.66 cells/HPF), (Fig. 3B,a–d). Rats
from groups III and IV showed very low number of posi-
tive stained cells in the renal interstitium (CD3+ cells: 2.15
± 0.28 cells/HPF and CD68+ cells: 1.10 ± 0.14 cells/HPF
and CD3+ cells: 2.90 ± 0.38 cells/HPF and CD68+ cells: 1
± 0.13 cells/HPF), respectively (see, Fig. 3B,e–h). Statisti-
cal significance comparing CD3+ and CD68+ infiltrated
cells quantification between group I and group II was
found (p < 0.001).
At-RA treatment reduces the expression of VCAM-1 in 
renal tissue. Expression of pro-inflammatory TNF-α and 
IL-1β cytokines
TNF-α and IL-1β are common mediators in inflammatory
processes, and they both regulate the expression of
VCAM-1. We therefore analyzed, by RT-PCR, the expres-
sion of these pro-inflammatory cytokines in total RNA
extracted from kidneys at day 13 of the disease in all the
experimental groups (Fig. 4A). In HgCl2-injected rats, the
levels of TNF-α and IL1-β were up-regulated in compari-
son with control rats (0.67 ± 0.23 and 0.59 ± 0.03 versus
0.15 ± 0.03 and 0.12 ± 0.004). However, rats injected with
HgCl2 and also treated with at-RA exhibited a pronounced
decrease of both cytokines expression (TNF-α: 0.07 ±
0.015 and IL-1β: 0.140 ± 0.05). In addition, western blot
analysis of VCAM-1 protein using total kidney lysates (Fig.
4B) showed an augmented expression of VCAM-1 at day
13 in rats only injected with HgCl2. Administration of at-
RA to HgCl2-injected rats caused a significant down-regu-
lation of VCAM-1 expression in the renal tissue. The
expression of VCAM-1 from rats treated only with at-RA
(group III) showed no significant differences respect to
those rats injected with vehicle (group IV). All together
these results indicate that at-RA treatment reduced VCAM-
1 expression in HgCl2-injected rats and this reduction may
be related to the diminished levels of TNF-α and IL-1β in
the renal tissue after at-RA treatment.
At-RA reduces the expression of VLA-4 integrin
Previous works reported that in this model of autoim-
mune nephritis, VLA-4/VCAM-1 is the principal adhesion
pathway for circulating leukocytes extravasation into
renal interstitium [8]. Therefore, we have studied the
effects of at-RA on VLA-4 integrin expression. PBLs
obtained at day 13 of the disease from all experimental
groups were incubated with HP2/1 (anti-α4 subunit of
VLA-4 integrin), and VLA-4 expression was analyzed by
flow cytometry. We found that VLA-4 membrane expres-
sion on leukocytes from HgCl2-injected rats (group I), was
significantly higher compared to that from control rats
(Fig 5A,a). Interestingly, the expression of this integrin
was significantly reduced in leukocytes from HgCl2-
injected rats treated with at-RA (Fig. 5A,b) (group II)
reaching basal levels. Leukocytes from rats treated with at-
RA alone (group III) and control rats showed similar lev-
els of VLA-4 expression, as shown in Fig. 5A,c and 5A,d
respectively.
Additionally, the expression of VLA-4 integrin was evalu-
ated in the infiltrated cells in the renal interstitium. About
80% of the mononuclear infiltrating cells were found pos-
itive for α4 integrin expression (Fig. 5B,a), being drasti-
cally reduced to 10 % when mercuric rats were also treated
with at-RA (Fig. 5B,b). Rats from groups III and IV did not
show any significant renal infiltrates.
At-RA modulates VLA-4 adhesion to sVCAM-1
In order to asses the effect of at-RA on VLA-4-dependent
adhesion, adhesion assays to VCAM-1 were performed
using K562-α4 cell treated with different at-RA doses (50,
100 and 500 nM) during 24, 48 and 72 h. Data shown in
Fig. 6 demonstrate that adhesion of K562-α4 cells to
VCAM-1 was inhibited by at-RA in a time and concentra-
tion dependent manner (Fig. 6).
Discussion
In the present work, we have described the beneficial
effect of at-RA in the model of autoimmune nephritis
induced by HgCl2, and identified VLA-4 as target for at-RA
in this experimental renal disease. Mercury induces in BN
rats a T-dependent polyclonal B cell activation resulting in
the development of an autoinmune response, with the
synthesis of auto-Ab, mainly anti-GBM IgG Ab. The anti-
GBM Ab was deposited along the GBM following a linear
pattern, thereby altering the glomerular filtration barrier
and contributing to the production of proteinuria [3] as
well as to the release of pro-inflammatory mediators [1-
3]. At-RA treatment has shown to be efficient in several
experimental models of renal diseases [16,21-25]. In these
studies, at-RA administration was associated with a reduc-
tion of inflammatory cell infiltrates as well as a decrease
in the expression of proinflammatory cytokines. In our
model, we have similarly demonstrated a beneficial effectBMC Nephrology 2007, 8:3 http://www.biomedcentral.com/1471-2369/8/3
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At-RA treatment decreases anti-GBM abs production and deposition along GBM Figure 2
At-RA treatment decreases anti-GBM abs production and deposition along GBM. A) Serum levels of circulating 
anti-GBM Abs in all experimental groups measured by ELISA. Results were expressed as percentage of binding relative to sam-
ples from positive control serum and presented as Mean ± SD;* P < 0.001 vs. vehicle group and °P < 0.001 vs. HgCl2 group. B) 
Glomerular deposits of IgG measured by direct immunofluorescence in kidney cryosections from HgCl2-injected rats (a), 
HgCl2-injected rats also treated with at-RA (b), rats treated only with at-RA (c) and injected with vehicle (d). Ig G fluorescence 
intensity quantification is shown on the right. Data are presented as mean ± SD; *P < 0.001 vs. vehicle group and °P < 0.001 vs. 
HgCl2 group.BMC Nephrology 2007, 8:3 http://www.biomedcentral.com/1471-2369/8/3
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of this compound in the outcome of the HgCl2-induced
autoimmune nephritis, by administration of at-RA from
day 0 of the experimental protocol. Moreover, we have
also reported a significant effect of at-RA on the VLA-4
expression in vivo not described up to the moment, point-
ing out this integrin as a target for at-RA action.
Our results demonstrate that at-RA significantly reduces
the production of circulating anti-GBM at day 13 and con-
sequently the deposition of this auto-Ab along the GBM
favoring the reduction of the proteinuria levels at day 13.
The capacity of at-RA to preserve the structure and func-
tion of podocytes, involved in the maintenance of the fil-
tration barrier, may also contribute to decrease
proteinuria at day 13 [16]. In addition, preliminary results
from our laboratory indicate that at-RA protects the prox-
imal tubule epithelium integrity against oxidative injury,
thus contributing to the reduction of proteinuria which is
due to mercury-induced tubular toxicity (M.M. Escribese
et al., unpublished observations).
Another essential feature of the inflammatory response in
HgCl2-induced nephritis is the appearance of a massive
cellular infiltrate localized in the periglomerular and
perivascular zone, including macrophages (CD68+) and T
lymphocytes (CD3+). The treatment with at-RA also abro-
gates this cell infiltration into the renal interstitium. In
fact, infiltrating cells were about 5-fold lower in rats
treated with at-RA than in HgCl2-injected rats.
Anti-α4 Ab administration has been shown to exert a pro-
tective effect against infiltration of the renal interstitium
accompanied by reduction of proteinuria and of auto-Ab
anti-GBM [8]. On the other hand, it has been demon-
strated that VLA-4 integrin participates in the immune
synapses necessary for the development of an immune
response. Moreover, the blockage of VLA-4 integrin, shifts
the immune response from Th2 to Th1 in vitro and in vivo
in the autoimmune nephritis induced by HgCl2 [9,10,26].
These works point out VLA-4 integrin as an essential mol-
ecule in the development this autoimmune nephritis.
In these report, we have described a significant effect of at-
RA on VLA-4 integrin expression and function. Indeed,
the number of cells positive for VLA-4 in the renal intersti-
tium was considerably lower in HgCl2-injected rats also
treated with at-RA than in mercuric rats. Moreover, the
expression of this integrin in PBLs from at-RA treated rats
was also significantly lower than in PBLs from mercuric
rats. These results clearly demonstrate that at-RA was able
to reduce to basal levels the expression of VLA-4 integrin
in leukocytes. The decrease in VLA-4 expression caused by
at-RA could contribute to the improvement of the out-
come of this autoimmune nephritis. Furthermore, our
data demonstrate that at-RA has an effect on the VLA-4-
Renal interstitial leukocyte infiltration is diminished by at-RA  treatment Figure 3
Renal interstitial leukocyte infiltration is diminished 
by at-RA treatment. A) Interstitial cell infiltration evalu-
ated by light microscopy in periodic acid-Shiff (PAS)-stained 
renal tissue. Representative images from HgCl2-injected rats 
(a) and HgCl2-injected rats and also treated with at-RA 15 
mg/Kg (b) are shown. B) Renal interstitial mononuclear cell 
infiltrates characterization. Immunoperoxidase staining for 
CD3+ and CD68+ cells in renal tissue at day 13 of the disease, 
from HgCl2-injected rats (a-b), from HgCl2-injected rats also 
treated with at-RA (c-d), from rats treated only with at-RA 
(e-f) and vehicle (g-h).BMC Nephrology 2007, 8:3 http://www.biomedcentral.com/1471-2369/8/3
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At-RA treatment reduces proinflammatory mediators and VCAM-1 expression in renal tissue Figure 4
At-RA treatment reduces proinflammatory mediators and VCAM-1 expression in renal tissue. A) Proinflamma-
tory cytokines mRNA analysis at day 13. Quantitative real-time RT-PCR of total RNA isolated from kidneys from all experi-
mental groups. Results normalized to β-actin are expressed as mean ± SD; *P < 0.001 vs. HgCl2-injected rats. B) Expression of 
VCAM-1 in total renal lysates estimated by Western Blot. On the right, quantification of VCAM-1 expression is expressed as 
the mean ± SD of the densitometry values, relative to actin;*P < 0.001 vs. HgCl2-injected rats.BMC Nephrology 2007, 8:3 http://www.biomedcentral.com/1471-2369/8/3
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VLA-4 integrin leukocyte expression is decreased by at-RA treatment Figure 5
VLA-4 integrin leukocyte expression is decreased by at-RA treatment. A) VLA-4 expression in PBLs from the four 
experimental groups. Flow cytometry analyses were performed using anti-α4 Ab (HP2/1) (continuous line) and anti-mouse IgG 
Ab as a negative control (discontinuous line). PBLs from HgCl2 -injected rats stained with anti-α4 (a), from HgCl2-injected rats 
also treated with at-RA (b), from rats only treated with at-RA (c) and from rats injected with vehicle (d). B) VLA-4 expression 
in cellular renal infiltrates at day 13. Anti-α4 immunoperoxidase staining of renal tissue from HgCl2-injected rats (a), HgCl2-
injected rats treated with at-RA (b), rats treated only with at-RA(c) and rats injected with vehicle (d)BMC Nephrology 2007, 8:3 http://www.biomedcentral.com/1471-2369/8/3
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dependent adhesion since the treatment of K564-α4 with
at-RA reduces the capacity of these cells to adhere to
VCAM-1 in a time and dose dependent manner. These in
vitro results could explain the reduction of cellular infil-
trates in renal interstitium in mercuric rats also treated
with at-RA. Then, our results strongly suggest that VLA-4
integrin is an in vivo target for this metabolite.
Our results show, for the first time in an in vivo experimen-
tal model of renal disease, that at-RA reduces the plasma
membrane expression of VLA-4 on PBLs from HgCl2-
injected rats, to the basal levels found on PBLs from
healthy rats. In vitro studies have shown that at-RA was
able to modulate the expression of integrins in different
cell lines as well as in primary leukocytes. Most studies
have examined the effects of at-RA on β2 integrin expres-
sion [27-30]. In this regard, it has been reported that at-RA
reduces the expression of all β2 integrins in primary
human monocytes and induces β2 integrin expression in
human monocytic cell lines THP-1 and U937 [11]. In our
experimental model of autoimmune nephritis, the expres-
sion of β2 integrins such as LFA-1 was not significantly
affected by at-RA treatment (data not shown), suggesting
the specificity of at-RA effect on the β1 integrin, VLA-4 in
our case. Regarding this, a limited number of studies had
addressed the in vitro effects of at-AR on β1 integrins
[31,32], even though it has been described that at-RA was
able to significantly alter the adhesion phenotype of the
acute promyelocytic leukemia cell line NB-4 under physi-
ologic flow conditions, by regulating cell surface expres-
sion of the α4β1 integrin [12].
At-RA reduced significantly the inflammatory response
developed in this nephritis model. It is well known that
the increase of VCAM-1 expression in renal tissue induced
by the pro-inflammatory cytokines TNF-α and IL-1β,
leads to circulating leukocytes recruitment via interactions
with their cognate ligands in endothelial cells [6]. In our
model of mercury-induced nephritis, the levels of TNF-α
and IL1-β cytokines as well as the expression of VCAM-1
molecule were significantly increased at day 13 of the dis-
ease in comparison with the controls. Pro-inflammatory
cytokines are responsible of the triggering and the mainte-
nance of a standard inflammatory response including the
one developed in our experimental model [33,34]. In fact,
when HgCl2-injected rats were treated with at-RA, the lev-
els of both cytokines were reduced, and the expression of
the endothelial adhesion molecule VCAM-1 decreased.
At-RA treatment blocks VLA-4-dependent cell adhesion Figure 6
At-RA treatment blocks VLA-4-dependent cell adhesion. The effects of at-RA in VLA-4-dependent adhesion was esti-
mated performing adhesion assays to VCAM-1. of K562-α4 treated with 50, 100 and 500 nM of at-RA during 24, 48 and 72 h. 
Cell adhesion was quantified in a fluorescence analyser previous labelling the cells with BCECF-AM. Data are presented as 
mean ± SD of triplicate of samples from three independent experiments. *P < 0.001 vs. non-treated K562-α4 cells.BMC Nephrology 2007, 8:3 http://www.biomedcentral.com/1471-2369/8/3
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These results suggest that the cytokine-mediated induc-
tion of VCAM-1 is prevented by at-RA treatment in our
model might be through a direct action of at-RA over the
VCAM-1 promoter and/or an indirect action of at-RA
down-regulating the levels of proinflammatory cytokines
involved on VCAM-1 expression. Further investigations to
shed light into both issues are necessary.
Conclusion
This work demonstrates that at-RA has a therapeutic effect
on the HgCl2-induced autoimmune nephritis in BN rats,
since this compound reduces significantly the inflamma-
tory and the autoimmune responses. Our results also
demonstrate that at-RA treatment reduces the membrane
expression of VLA-4 on circulating PBLs, diminishes
VCAM-1 expression in renal tissue and blocks VLA-4
dependent adhesion. In summary, our findings strongly
suggest that VLA-4 is a target for at-RA in vivo and that at-
RA could be considered as a therapeutic agent in those dis-
eases where VLA-4/VCAM-1-dependent adhesion plays an
essential role.
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